Can a phone app ease stress for childhood cancer survivors?
NCT ID NCT06053268
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study looks at whether a daily mindfulness app called Headspace can help adults who survived childhood cancer cope with stress. Fifty survivors will use the app for 30 days and wear a wrist device to track stress signs. The main goal is to see if people find the app acceptable and easy to use, not yet to prove it reduces stress.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Headspace mobile mindfulness app
- What this could lead to
- If it works, this could point toward a simple, low-cost way to help childhood cancer survivors manage stress and improve their health.
- What could go wrong
- This is a very small, early feasibility study with only 50 participants. It is not designed to prove the app reduces stress, only that people will use it and that data collection methods work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
May 2024
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Research participant is at least 18 years old at enrollment * Research participant is followed by St. Jude Children's Research Hospital (SJCRH) * Research participant has a diagnosis history of leukemia or lymphoma * Research participant takes part in the St. Jude Lifetime Cohort Study (SJLIFE) * Research participant has elevated psychological stress scores of 6 or greater on most recent SJLIFE questionnaire * Participant can speak and read English Exclusion Criteria: * Research participant currently engages in mindful stress-reduction practices \>2x per week (e.g., tai chi, meditation) * Research participant takes psychiatric medications or medications that impact cardiac functioning, beta-blockers, alpha-blockers * Research participant wears a pacemaker * Research participant has a diagnosis of a congenital heart disease * Research participant has no access to a smartphone * Research participant has elevated pain interference scores (T≥70)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Childhood cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The forgotten siblings: can two surveys give voice to children living beside a brother or sister with cancer?
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Reprogrammed immune cells target CD30-Positive lymphoma in early trial
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- Double-Drug attack on Hard-to-Treat lymphomas
- Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm